CLDN18.2-Targeted Therapies | Oncology Modality Intelligence

Description

List of Tables

Claudin 18.2 went from an obscure tight-junction protein to one of oncology's most crowded targets in a few years, and Japan holds a unique position in the class: it gave the world its first CLDN18.2 approval. Astellas's Vyloy, a monoclonal antibody against CLDN18.2, was cleared by the PMDA in March 2024 for CLDN18.2-positive, HER2-negative gastric and gastroesophageal junction adenocarcinoma, ahead of any other major regulator. That decision made Japan the proving ground for a biomarker-defined gastric cancer segment and put a Japanese company at the head of a target class that Chinese developers are now flooding with next-generation molecules.

The tension is generational. Vyloy validated the target but leaves obvious room for better: its antibody format requires high CLDN18.2 expression and combination chemotherapy, and its efficacy profile invites challenge. Chinese developers have answered with antibody-drug conjugates, bispecifics, and CAR-T cells against the same target - Innovent's IBI343 has moved fastest, with a Chinese NDA filed in June 2026 - and Western firms have licensed heavily into the class, with AstraZeneca, GSK, and Astellas itself all securing CLDN18.2 ADC assets. The unresolved questions are which modality wins on tolerability and depth of response, how the companion diagnostic standard settles as thresholds vary across programs, and whether Japan's first-mover position converts into durable market structure or merely an early data advantage.

This report maps the CLDN18.2 class with Japan as anchor. It explains the biology and expression testing that define the eligible population, walks through the SPOTLIGHT and GLOW programs behind Vyloy, and profiles every meaningful challenger: the ADCs of Innovent, CSPC, AstraZeneca, GSK's Hansoh-licensed asset, Elevation Oncology, LaNova, and Astellas's own May 2025 in-licensing; the mAbs of Transcenta; the bispecific programs of Akeso; and CARsgen's CLDN18.2 CAR-T. Chapters also cover the VENTANA companion diagnostic standard, PMDA precedent value, and China-to-Japan competitive spillover.

The report serves oncology BD teams evaluating CLDN18.2 assets, investors pricing the class, diagnostics firms tracking IHC standardization, and Astellas competitors and partners. It provides program-by-program detail sufficient for benchmarking, licensing diligence, and Japan entry planning.

Scope and Coverage: The report covers CLDN18.2-targeted mAbs, ADCs, bispecifics, and cell therapies in development or approved for gastric, GEJ, pancreatic, and other CLDN18.2-expressing tumors, with Japan's regulatory precedent as focal point. It profiles Astellas, Innovent, AstraZeneca, GSK, Transcenta, CARsgen, Akeso, Hansoh, CSPC, Elevation Oncology, and LaNova, plus the companion-diagnostic layer.

Report Highlights:

Reconstructs the SPOTLIGHT and GLOW programs behind Vyloy's first-in-world Japan approval
Maps the CLDN18.2 ADC wave, including Innovent's IBI343 and Astellas's in-licensed asset
Covers CLDN18.2 bispecifics and CARsgen's satricabtagene autoleucel CAR-T
Explains CLDN18.2 IHC testing standards and threshold variation across programs
Analyzes China-to-Japan competitive dynamics and licensing structures
Frames modality-selection questions for BD and investment decisions

Product Code: JPH-028

Table of Content

1. Executive Summary

2. CLDN18.2-Targeted Therapies: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Astellas (JP) - Vyloy (zolbetuximab) first-in-world CLDN18.2 mAb approval; in-licensed a CLDN18.2 ADC in May 2025
AstraZeneca (UK) - CLDN18.2 ADC (CMG901) licensed from KYM Biosciences
GSK (UK) - licensee of a Hansoh CLDN18.2 ADC
Innovent (CN) - IBI343 CLDN18.2 ADC; China NDA filed June 2026
Akeso (CN) - CLDN18.2 bispecific and IO pipeline
Transcenta (CN) - osemitamab CLDN18.2 mAb
Hansoh Pharmaceutical (CN) - CLDN18.2 ADC licensed to GSK
CARsgen (CN) - satricabtagen autoleucel CLDN18.2 CAR-T
LaNova Medicines (CN) - CLDN18.2 ADC licensed to AstraZeneca
Elevation Oncology (US) - EO-3021 CLDN18.2 ADC licensed from CSPC
CSPC Pharmaceutical (CN) - SYSA1801 CLDN18.2 ADC originator

Product Code: JPH-028

List of Tables

Table 1. Claudin 18.2 Biology: Expression Pattern and Druggability
Table 2. CLDN18.2 Expression Testing: IHC Assays and Scoring Frameworks
Table 3. VENTANA CLDN18 (43-14A) RxDx Companion Diagnostic: Design and Japan Status
Table 4. Threshold Variation Across CLDN18.2 Programs: Comparability Framework
Table 5. Vyloy (Zolbetuximab): Mechanism, Formulation, and Combination Backbone
Table 6. SPOTLIGHT Trial: Design, Population, and Biomarker Criteria
Table 7. GLOW Trial: Design, Population, and Biomarker Criteria
Table 8. Vyloy Japan Approval: PMDA Review Path and Label Structure
Table 9. Vyloy NHI Listing and Hospital Adoption Requirements
Table 10. Vyloy Safety Management: Nausea and Infusion Protocols
Table 11. Zolbetuximab Development Beyond Gastric: Pancreatic and Other Programs
Table 12. Astellas CLDN18.2 ADC In-Licensing of May 2025: Asset Profile and Deal Structure
Table 13. Innovent IBI343: ADC Design and Clinical Program
Table 14. IBI343 China NDA Filing of June 2026: Contents and Implications for Japan
Table 15. CSPC SYSA1801: CLDN18.2 ADC Originator Program
Table 16. Elevation Oncology EO-3021: Ex-China Development Strategy
Table 17. AstraZeneca CMG901 (KYM Biosciences-Licensed): Program Status
Table 18. GSK's Hansoh-Licensed CLDN18.2 ADC: Program Structure
Table 19. LaNova Medicines CLDN18.2 ADC and AstraZeneca Licensing Relationship
Table 20. Transcenta Osemitamab: TranStar Program Designs
Table 21. Akeso CLDN18.2 Bispecific and IO Pipeline Programs
Table 22. CARsgen Satricabtagene Autoleucel: CLDN18.2 CAR-T Program in Gastric Cancer
Table 23. Modality Comparison Framework: mAb vs ADC vs Bispecific vs CAR-T Against CLDN18.2
Table 24. Tolerability Differentiators Across CLDN18.2 Modalities
Table 25. Payload and Linker Choices Among CLDN18.2 ADCs
Table 26. Pancreatic Cancer as a CLDN18.2 Expansion Opportunity: Program Scan
Table 27. China CLDN18.2 Development Landscape: Density and Licensing-Out Record
Table 28. China-to-Japan Asset Migration Patterns in the CLDN18.2 Class
Table 29. PMDA Precedent Value of the Vyloy Review for Follow-On Filings
Table 30. Regulatory Pathways for CLDN18.2 ADCs in Japan
Table 31. Biomarker Testing Infrastructure for CLDN18.2 in Japanese Hospitals
Table 32. Pathology Workflow Integration for CLDN18.2, HER2, and PD-L1 Testing
Table 33. Eligible Population Definition Under Alternative Expression Thresholds
Table 34. Gastric Cancer Biomarker-Defined Segment Map in Japan
Table 35. Competitive Positioning Matrix: CLDN18.2 Assets by Modality and Stage
Table 36. Deal Benchmarks for CLDN18.2 Licensing Transactions
Table 37. Patent and Intellectual-Property Landscape for CLDN18.2 Targeting
Table 38. Clinical Trial Enrollment Competition in Gastric Cancer Biomarker Segments
Table 39. Manufacturing Considerations for CLDN18.2 ADCs and Cell Therapies
Table 40. Combination Strategies Pairing CLDN18.2 Agents with Checkpoint Inhibitors
Table 41. Sequencing Framework: CLDN18.2, HER2, and PD-L1 Directed Therapy in Gastric Cancer
Table 42. Pricing and Reimbursement Precedents for Biomarker-Defined Gastric Therapies
Table 43. Hospital Adoption Barriers for New Biomarker-Defined Gastric Regimens
Table 44. Scenario Framework: CLDN18.2 Class Leadership Paths
Table 45. Risk Register: Tolerability, Threshold Shifts, and China Competition
Table 46. Indicator Dashboard for CLDN18.2 Class Monitoring
Table 47. Due-Diligence Checklist for CLDN18.2 Asset Licensing
Table 48. Stakeholder Position Map: Sponsors, Diagnostics, and Payers
Table 49. Beyond Gastrointestinal: CLDN18.2 Expression in Other Tumor Types
Table 50. Analytical Appendix: Trial Registries, PMDA Documents, and Deal Sources

List of Figures

Figure 1. CLDN18.2 Target Biology and Antibody Binding Model
Figure 2. CLDN18.2 IHC Testing and Scoring Workflow
Figure 3. VENTANA Companion Diagnostic Role in the Treatment Pathway
Figure 4. Threshold Comparability Map Across Programs
Figure 5. Vyloy Mechanism and Combination Backbone Diagram
Figure 6. SPOTLIGHT and GLOW Trial Design Schematics
Figure 7. Vyloy Japan Approval Timeline
Figure 8. Vyloy Hospital Adoption and Safety-Management Flow
Figure 9. Zolbetuximab Lifecycle Development Map
Figure 10. Astellas CLDN18.2 Deal History Diagram
Figure 11. IBI343 Program Map and China NDA Path
Figure 12. CSPC, Elevation, and EO-3021 Program Diagram
Figure 13. AstraZeneca and GSK Licensed ADC Program Map
Figure 14. Transcenta Osemitamab TranStar Program Tree
Figure 15. Akeso CLDN18.2 Bispecific Program Structure
Figure 16. CARsgen CLDN18.2 CAR-T Program Diagram
Figure 17. Modality Comparison Matrix for CLDN18.2 Targeting
Figure 18. Tolerability Differentiation Framework
Figure 19. Payload and Linker Design Map Among CLDN18.2 ADCs
Figure 20. Pancreatic Expansion Opportunity Map
Figure 21. China CLDN18.2 Landscape Density Diagram
Figure 22. China-to-Japan Asset Migration Flow
Figure 23. PMDA Precedent Chain from Vyloy to Follow-Ons
Figure 24. Regulatory Pathway Map for CLDN18.2 ADCs in Japan
Figure 25. Biomarker Testing Infrastructure Map in Japanese Hospitals
Figure 26. Pathology Workflow for CLDN18.2, HER2, and PD-L1
Figure 27. Eligible Population Under Alternative Thresholds
Figure 28. Gastric Cancer Biomarker Segment Map
Figure 29. Competitive Positioning Map: CLDN18.2 Assets
Figure 30. CLDN18.2 Licensing Deal Benchmark Framework
Figure 31. IP Landscape Map for CLDN18.2 Targeting
Figure 32. Enrollment Competition Dynamics in Biomarker Segments
Figure 33. Manufacturing Considerations Diagram for ADCs and CAR-T
Figure 34. Checkpoint Combination Strategy Map
Figure 35. Gastric Cancer Sequencing Framework with CLDN18.2
Figure 36. Pricing Precedent Map for Biomarker-Defined Gastric Therapy
Figure 37. Hospital Adoption Barrier Framework
Figure 38. Scenario Tree: CLDN18.2 Class Leadership
Figure 39. Risk Map: Tolerability, Thresholds, and China Competition
Figure 40. CLDN18.2 Class Monitoring Dashboard
Figure 41. Licensing Due-Diligence Flow
Figure 42. Stakeholder Position Map
Figure 43. CLDN18.2 Expression Across Tumor Types
Figure 44. Patient Journey from Endoscopy to CLDN18.2-Directed Therapy
Figure 45. Diagnostic-Lab Readiness Framework for CLDN18.2 Testing
Figure 46. Sponsor Trial-Network Footprints in Japanese Gastric Cancer
Figure 47. Investor KPI Dashboard for the CLDN18.2 Theme
Figure 48. Competitive Response Options for Late Entrants
Figure 49. Synthesis: What Decides CLDN18.2 Leadership in Japan
Figure 50. Report Roadmap: Chapter Linkages to Reader Decisions

CLDN18.2-Targeted Therapies | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. CLDN18.2-Targeted Therapies: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures